Pitavastatin Use in Patients with Previous Statin Intolerance

Abstract

65.3% HIV+ (P 5 .0007). HIV+/HIV2 groups had similar levels of serum triglycerides, apoB, and LDL-C. HIV+ had greater LDL-P (1719 vs. 1514 nmol/L; P 5 .04), lower HDL-C (44 vs. 58 mg/dL; P , .0001), lower HDL-P (30 vs. 35 nmol/L, P 5 .0015), and were more likely to be on a statin drug. HIV+ had an LDL-P mean 1719 vs. 1514 nmol/L for HIV2, P 5 .03. HIVhad an LDL-C mean of 100 vs. 112mg/dL for HIV+, P 5 .09. LDL-P and LDL-C were weakly correlated (r 5 0.34) for both groups. In the HIV2 group, LDL-P and LDL-Cwere negatively discordant in 18% of patients and positively discordant in 51% of patients. In contrast, HIV+ patients showed 48% negative discordance and 20% positive discordance. Conclusion: LDL-C and LDL-P were poorly correlated in both HIV2 and HIV+ groups, but the HIV+ group had a significantly greater proportion of patients with LDL-P . LDL-C. This suggests that measurement of LDL-C in this population of HIV-infected patients may underestimate atherogenic burden and risk for CVD.